Bioprocessing of Viral Vectors and Vaccines

病毒载体和疫苗的生物加工

• 批准号: CRC-2021-00032
• 负责人: Kamen, Amine
• 金额: $ 14.57万
• 依托单位: McGill University
• 依托单位国家: 加拿大
• 项目类别: Canada Research Chairs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=744429
• 关键词: Bioprocessing; Viral; Vectors; Vaccines

The major accomplishments achieved by the chair during the previous term include: - Acceleration of influenza seed stocks generation from months to weeks to enable rapid vaccine manufacturing in response to pandemic situations using cell culture technology and reverse engineering.- Development and technology transfer of manufacturing process for adenovirus-vectored vaccine against Newcastle Disease infection for protection of livestock in Ethiopia. - Advanced process development of a Vero cell line production platform operated in suspension and serum free media for manufacturing of recombinant Vesicular Stomatitis Virus-vectored vaccine against Ebola, HIV and SARS-CoV-2 candidate vaccines.- Capacity building and Highly Qualified Perosonnel (HQP) training in Canada and abroad to support preparedness plans in response to emerging and re-emerging infectious diseases.Building on these impactful achievements, that are currently used by industry for accelerated development of vectored vaccines against COVID-19 pandemic, the proposed CRC Tier 1 research program in Bioprocess Sciences and Technology of Viral Vectors and Vaccines focuses on reverse engineering of complex biological systems and dynamics of cell/virus interaction to design advanced manufacturing processes for safe, efficacious and cost-effective vaccines and delivery systems for in-vivo gene editing. A system approach integrating 1) genome-scale re-design of viral and cellular biological platforms, 2) continuous process acceleration and intensification, 3) process analytical technologies and data sciences, to support the delivery of high-value medicines in response to emerging and re-emerging infectious diseases. The research program builds on long-lasting collaborations with industrial and institutional partners to support translation of novel technologies and support commercialization of high value viral-based products. The program is also designed to provide solid training for HQPs to meet the needs of the Canadian biomanufacturing industry and build sustained capacity in the strategic area of advanced vaccine manufacturing.

主席在上一届任期内取得的主要成就包括：-将流感种子库存的生成从几个月加快到几周，以便能够利用细胞培养技术和反向工程快速制造疫苗，以应对大流行情况。-开发和技术转让用于保护埃塞俄比亚家畜的新城疫感染的腺病毒载体疫苗的制造过程。-先进工艺开发Vero细胞系生产平台，在悬浮和无血清介质中运行，用于生产针对埃博拉、艾滋病毒和SARS-CoV-2候选疫苗的重组水泡性口炎病毒载体疫苗。-加拿大和海外的能力建设和高质量的Perosonnel(HQP)培训，以支持应对新出现和再次出现的传染病的准备计划。基于这些有影响力的成就，目前业界正在利用这些成果来加快开发针对新冠肺炎大流行的载体疫苗。拟议的CRC第1级生物过程科学和病毒载体和疫苗技术研究计划专注于复杂生物系统的反向工程和细胞/病毒相互作用的动力学，以设计安全、有效和具有成本效益的疫苗和体内基因编辑递送系统的先进制造工艺。一种系统方法，包括1)病毒和细胞生物平台的基因组规模重新设计，2)持续的过程加速和强化，3)过程分析技术和数据科学，以支持高价值药物的交付，以应对新出现和重新出现的传染病。该研究计划建立在与行业和机构合作伙伴的长期合作基础上，以支持新技术的转化和高价值病毒产品的商业化。该计划还旨在为HQP提供扎实的培训，以满足加拿大生物制造行业的需求，并在先进疫苗制造的战略领域建立持续的能力。